Lipoprotein(a): The Genetic Risk Factor Most People Have Never Heard Of

You've probably never heard of lipoprotein(a). Your doctor may not have mentioned it. It doesn't show up on standard cholesterol panels (Lp(a) pathophysiology and treatment perspectives). Yet this single molecule, determined almost entirely by the genes you inherited, can quietly double or triple your risk of heart attack and stroke regardless of how well you eat, how much you exercise, or how low your LDL cholesterol sits. Unlike nearly every other cardiovascular risk factor, lipoprotein(a) doesn't respond to the interventions we've been told matter most (AHA on lipoprotein(a) as a genetic risk factor) (Cleveland Clinic on who needs Lp(a) testing) (AHA Scientific Statement: Lp(a) as a causal risk factor for atherosclerotic CVD).

Key Takeaways

• Lipoprotein(a) levels are 80-90% genetically determined and set at birth.
• Elevated Lp(a) independently raises cardiovascular disease risk even with normal cholesterol.
• Diet and exercise have minimal to no effect on Lp(a) levels.
• One in five people worldwide has high Lp(a), making it common.
• Standard lipid panels don't measure Lp(a), requiring a separate test.
• Current treatment options are limited but new therapies are in development.
• Lp(a) promotes both atherosclerosis and thrombosis through multiple mechanisms.

What Lipoprotein(a) Actually Is at a Molecular Level

Lipoprotein(a) is a cholesterol-carrying particle that looks structurally similar to LDL cholesterol but with a critical difference: it has an additional protein called apolipoprotein(a), or apo(a), attached to its surface. This apo(a) protein is what makes Lp(a) uniquely problematic.

The particle consists of the following components:

• An LDL-like core containing cholesterol and triglycerides
• Apolipoprotein B-100 (the same protein found in LDL) surrounding the core
• Apo(a) covalently bound through a disulfide bridge

The apo(a) protein has a structure that resembles plasminogen, a molecule involved in breaking down blood clots. This structural similarity allows Lp(a) to interfere with normal clot dissolution, promoting thrombosis. The size of the apo(a) protein varies dramatically between individuals due to genetic variation in the LPA gene, which contains a variable number of repeated sequences called kringles. Smaller apo(a) isoforms are associated with higher Lp(a) levels and greater cardiovascular risk.

What makes Lp(a) fundamentally different from other lipoproteins is that its concentration in your blood is almost entirely determined by your genetics. While LDL cholesterol responds to diet, statins, and lifestyle changes, Lp(a) levels are established by your DNA and remain relatively stable throughout adult life. The LPA gene accounts for roughly 90% of the variation in Lp(a) levels between individuals, making it one of the most heritable cardiovascular risk factors known.

How Elevated Lp(a) Drives Cardiovascular Disease

Elevated Lp(a) accelerates cardiovascular disease through two primary mechanisms: promoting atherosclerosis and enhancing thrombosis.

Atherosclerosis promotion

Lp(a) particles penetrate the arterial wall more readily than standard LDL particles. Once inside the vessel wall, Lp(a) becomes oxidized and triggers inflammatory responses that recruit immune cells, particularly monocytes and macrophages, to the site. These immune cells engulf the oxidized Lp(a), forming foam cells that contribute to plaque buildup.

The cholesterol content of Lp(a) adds to the total cholesterol burden in arterial plaques, but the apo(a) component creates additional problems. Apo(a) carries oxidized phospholipids that amplify inflammation and promote endothelial dysfunction, impairing the ability of blood vessels to dilate properly. This inflammatory cascade accelerates plaque formation and makes existing plaques more unstable and prone to rupture.

Thrombosis enhancement

The structural similarity between apo(a) and plasminogen allows Lp(a) to competitively inhibit plasminogen binding to fibrin, the protein scaffold of blood clots. This interference reduces the body's ability to dissolve clots naturally. Additionally, Lp(a) enhances platelet activation and increases the expression of tissue factor, a key initiator of the clotting cascade. The net effect is a prothrombotic state where clots form more easily and dissolve more slowly, increasing the risk of acute cardiovascular events like heart attack and stroke (Lp(a) as an independent, genetic, and causal factor for CVD).

Valvular disease contribution

Lp(a) also contributes to calcific aortic valve stenosis, a condition where calcium deposits stiffen the aortic valve. The mechanism involves Lp(a) promoting inflammation and calcification in valve tissue, independent of its effects on coronary arteries. This makes elevated Lp(a) a risk factor not just for coronary artery disease but also for valvular heart disease.

Why Lp(a) Levels Are Locked In by Genetics

The LPA gene, located on chromosome 6, contains instructions for producing the apo(a) protein. What makes this gene unusual is a region with a variable number of tandem repeats called kringle IV type 2 (KIV-2) domains. The number of these repeats varies widely between individuals, ranging from as few as 3 to more than 40 copies. Smaller apo(a) isoforms, produced by genes with fewer KIV-2 repeats, are associated with higher circulating Lp(a) levels and increased cardiovascular risk.

This genetic architecture means that your Lp(a) level is essentially determined at conception. Unlike LDL cholesterol, which is influenced by hepatic cholesterol synthesis, dietary cholesterol intake, and receptor-mediated clearance, Lp(a) production and clearance rates are largely fixed by your genetic makeup. The liver produces Lp(a), but the rate of production is dictated by the LPA gene variants you inherited from your parents.

Lp(a) levels also vary significantly by ancestry:

• People of African descent tend to have higher median Lp(a) levels compared to those of European or Asian descent
• The range within any population is wide, reflecting different evolutionary pressures and genetic drift
• The relationship between Lp(a) levels and cardiovascular risk appears consistent across ancestries

Because Lp(a) is so genetically determined, it remains stable across the lifespan. Levels are established in childhood and change little in response to aging, weight fluctuations, or metabolic shifts. This stability is both a diagnostic advantage (since a single measurement reflects long-term exposure) and a therapeutic challenge (since conventional lipid-lowering strategies have minimal impact).

Why Standard Interventions Don't Work

The genetic determination of Lp(a) explains why the lifestyle interventions that effectively lower LDL cholesterol have little to no effect on Lp(a). Dietary changes, including low-fat diets, Mediterranean diets, and even extreme caloric restriction, do not meaningfully reduce Lp(a) levels. Exercise, whether aerobic or resistance training, similarly fails to move the needle. Weight loss, which can dramatically improve insulin sensitivity and lower triglycerides, leaves Lp(a) unchanged.

Common lipid-lowering medications show varying effects on Lp(a):

• Statins either have no effect on Lp(a) or may slightly increase levels in some individuals through upregulation of hepatic lipoprotein production.
• Ezetimibe produces modest Lp(a) reductions of around 7%, small relative to the magnitude of risk conferred by elevated Lp(a).
• PCSK9 inhibitors reduce Lp(a) by approximately 20-30%, with greater absolute reduction in those with higher baseline levels.
• Niacin can lower Lp(a) by 20-25% but has fallen out of favor due to lack of cardiovascular benefit in clinical trials and significant side effects.

PCSK9 inhibitors represent the most effective currently available pharmacologic option for Lp(a) reduction, but they are not specifically indicated for this purpose and are typically reserved for patients with very high LDL cholesterol or established cardiovascular disease.

The Only Proven Treatment and What's Coming

Lipoprotein apheresis is currently the only FDA-approved therapy specifically for lowering Lp(a). This procedure, similar to dialysis, physically removes Lp(a) and LDL cholesterol from the blood by passing it through a filtration system. Apheresis can reduce Lp(a) levels by 60-75% acutely, though levels gradually rise again between treatments. Patients typically undergo apheresis every one to two weeks, with each session lasting two to three hours.

Apheresis is reserved for individuals with very high Lp(a) levels (typically above 60 mg/dL or 150 nmol/L) who have progressive cardiovascular disease despite optimal medical therapy. The procedure is invasive, time-consuming, expensive, and not widely available. Long-term data suggest that regular apheresis reduces cardiovascular events in high-risk patients, but access remains limited and the burden of treatment is substantial.

The therapeutic landscape for Lp(a) is changing rapidly. Several targeted therapies are in late-stage clinical trials:

• Antisense oligonucleotides (ASOs) silence the LPA gene in the liver and reduce Lp(a) levels by 80-90% with dosing every few months.
• Small interfering RNAs (siRNAs) work through a similar mechanism, preventing the liver from producing apo(a) and thereby reducing Lp(a) assembly and secretion.
• Early-phase trials have demonstrated dramatic Lp(a) reductions with acceptable safety profiles.

Large cardiovascular outcomes trials are now underway to determine whether lowering Lp(a) with these drugs actually reduces heart attacks, strokes, and cardiovascular death. If successful, these therapies could become the first treatments specifically approved for elevated Lp(a), fundamentally changing how we approach this genetic risk factor.

Who Should Be Tested and What the Numbers Mean

Current guidelines recommend lipoprotein(a) testing at least once in adulthood for individuals with a personal or family history of premature cardiovascular disease, recurrent cardiovascular events despite statin therapy, or familial hypercholesterolemia. Some experts advocate for universal screening given the high prevalence of elevated Lp(a) and the fact that it cannot be predicted from standard lipid panels or clinical risk factors.

Lp(a) is measured in either mass units (mg/dL) or molar units (nmol/L). The lack of standardization between assays has historically complicated interpretation, but newer assays are improving consistency.

Risk categories are defined as follows:

• Low risk: below 30 mg/dL or 75 nmol/L
• Intermediate risk: 30-50 mg/dL (75-125 nmol/L)
• High risk: above 50 mg/dL (125 nmol/L)
• Very high risk: above 100 mg/dL (250 nmol/L), seen in roughly 5-10% of the population

The relationship between Lp(a) and cardiovascular risk is continuous and log-linear, meaning risk increases progressively with higher levels without a clear threshold. Even moderately elevated Lp(a) in the 30-50 mg/dL range increases risk, particularly when combined with other risk factors like elevated apolipoprotein B, high blood pressure, or diabetes. The presence of elevated Lp(a) should prompt aggressive management of modifiable risk factors, even if Lp(a) itself cannot be lowered with current therapies.

Because Lp(a) levels are stable over time, a single measurement is sufficient for risk stratification. Repeat testing is not necessary unless there is a specific clinical indication or the patient is enrolled in a trial of Lp(a)-lowering therapy. Family screening may be warranted when elevated Lp(a) is identified, as first-degree relatives have a 50% chance of inheriting the same high-risk LPA gene variant.

Measuring What Matters for Cardiovascular Longevity

Understanding your Lp(a) level is one piece of a comprehensive cardiovascular risk assessment. While Lp(a) itself may not be modifiable with current therapies, knowing your level informs how aggressively to manage other risk factors. Individuals with elevated Lp(a) benefit from tighter control of LDL cholesterol, often targeting levels well below standard guidelines. This typically means maximizing statin therapy, adding ezetimibe, and considering PCSK9 inhibitors when LDL remains elevated.

A complete cardiovascular risk profile includes these key markers:

• Apolipoprotein B measures the total number of atherogenic particles in your blood.
• High-sensitivity C-reactive protein serves as a marker of systemic inflammation.
• Homocysteine reflects methylation status and vascular health.
• Hemoglobin A1c assesses glycemic control over time.

Elevated Lp(a) also underscores the importance of non-lipid risk factors. Blood pressure control becomes even more critical, as hypertension and elevated Lp(a) synergistically increase risk. Smoking cessation is essential, as smoking amplifies the thrombotic risk associated with high Lp(a). Maintaining insulin sensitivity through diet and exercise, while not affecting Lp(a) directly, reduces overall cardiovascular burden.

If you want to understand your cardiovascular risk beyond what standard cholesterol testing reveals, Superpower's Baseline Blood Panel includes lipoprotein(a) alongside apolipoprotein B, high-sensitivity CRP, and comprehensive lipid fractionation. For those seeking deeper insight into metabolic and inflammatory drivers of cardiovascular disease, the Advanced Blood Panel adds markers like insulin resistance scoring and advanced lipoprotein particle analysis. These panels give you the data to track the factors that actually determine how your cardiovascular system is aging, not just how your cholesterol looks on paper.